ArticleThe Journal of biological chemistry2026
TIMELESS promotes glioma stemness and malignancy through JAK-STAT3 pathway.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common primary tumors of the central nervous system. Among them, glioblastoma (GBM), a World Health Organization (WHO) grade 4 glioma, is the most aggressive form and remains one of the most lethal human cancers. Its poor prognosis is largely attributable to rapid progression, frequent recurrence, and profound therapeutic resistance, all of which are closely associated with glioma stem cells (GSCs). Although several signaling pathways sustaining GSC properties have been identified, upstream regulators that coordinate these pathways remain incompletely understood. TIMELESS, originally identified as a component of the circadian clock, has recently been implicated in the regulation of brain function and is aberrantly overexpressed in multiple cancer types; however, its role in glioma malignancy has not been defined. Here, we demonstrate that TIMELESS mRNA expression increases with glioma grade and is associated with poor prognosis across multiple glioma cohorts. Genetic depletion of Timeless suppressed tumor aggressiveness and prolonged survival in an orthotopic mouse glioma model by attenuating GSC properties. Mechanistically, TIMELESS enhanced stemness of glioma by upregulating Janus kinases (JAK) expression and promoting phosphorylation of signal transducer and activator of transcription 3 (STAT3). These effects were conserved in human GBM cells, supporting the relevance of TIMELESS-mediated signaling across species. Together, our findings uncover an unexpected, clock-independent function of TIMELESS in sustaining glioma stemness and malignancy and highlight the TIMELESS-JAK-STAT3 axis as a noncanonical mechanism that operates beyond the traditional circadian clockwork in treatment-resistant glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.